GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXXWY) » Definitions » 3-Year EPS without NRI Growth Rate
中文

WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) 3-Year EPS without NRI Growth Rate : 55.80% (As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) 3-Year EPS without NRI Growth Rate?

WuXi Biologics (Cayman)'s EPS without NRI for the six months ended in Jun. 2023 was $0.18.

During the past 12 months, WuXi Biologics (Cayman)'s average EPS without NRI Growth Rate was 4.70% per year. During the past 3 years, the average EPS without NRI Growth Rate was 55.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 55.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of WuXi Biologics (Cayman) was 138.10% per year. The lowest was 49.30% per year. And the median was 59.60% per year.


Competitive Comparison of WuXi Biologics (Cayman)'s 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman)'s 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s 3-Year EPS without NRI Growth Rate falls into.



WuXi Biologics (Cayman) 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


WuXi Biologics (Cayman)  (OTCPK:WXXWY) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


WuXi Biologics (Cayman) 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Business Description

Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.